Facchinetti F, et al. – An analysis was set up to find out LKB1/STK11 mutations in non–small cell lung cancer (NSCLC) patients. No specific association was observed between STK11 mutations and clinico–pathological features, and STK11 mutations did not impact upon survival, in the cohort enriched for advanced NSCLC patients who received platinum–based chemotherapy. STK11 was positively correlated to KRAS mutations.